MedTrace Logo

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

NCT02689219 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-12-10

Study results available
· View outcomes & findings →

Summary

This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).

Conditions

  • Germ Cell Tumors
  • Testis Cancer
  • Testicular Cancer
  • Embryonal Carcinoma
  • Nonseminomatous Germ Cell Tumor

Interventions

DRUG

Brentuximab Vedotin

Both cohorts will be treated similarly and in parallel but analyzed separately.

Sponsors & Collaborators

  • Nabil Adra

    lead OTHER

Principal Investigators

  • Costantine Albany, MD · Indiana University School of Medicine, Indiana University Simon Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-09
Primary Completion
2018-11-13
Completion
2019-01-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02689219 on ClinicalTrials.gov